Turpaz in the first quarter: growth is strong, the test has shifted to acquisition digestion

Turpaz did not publish just another growth quarter. It published a quarter that changes the question investors should ask in 2026. Sales rose to $83.6 million, currency-neutral organic growth was 9%, and gross margin improved to 41.9%. That is enough to show that demand is not only acquisition-driven, and that specialty fine ingredients are starting to look steadier after a noisy 2025. Still, operating profit did not expand as a percentage of sales: excluding other expenses, the operating margin stayed at 16.0%, and part of the jump in net profit came from non-cash finance income related to Attractive Scent. After the Phoenix acquisition in the United States and the Romessence acquisition in France, the main test has moved from whether the company can buy growth to whether it can digest it. The next few quarters need to show that new sales preserve margins, that the U.S. synergies actually arrive, and that cash flow joins the story rather than leaving the income statement to carry it alone.

Company Snapshot

Turpaz is a flavors, fragrances, and specialty fine ingredients group with a dual growth machine: organic growth plus frequent acquisitions. At the end of the first quarter it sold to more than 4,800 customers in more than 95 countries and operated 30 production sites, R&D centers, laboratories, and sales and marketing offices. This is no longer a small Israeli platform that bought a few overseas assets. It is a global F&F platform trying to move up the industry ladder through small and mid-sized acquisition targets.

The advantage of the model is clear. The company can buy know-how, customers, and geographic access, then try to extract cross-selling, purchasing efficiency, and cost improvement. The friction is just as clear: the more acquisitions it makes, the harder it becomes to separate high-quality growth from balance-sheet expansion, purchase liabilities, and intangible assets. The previous annual analysis framed 2026 as a test of capital discipline and acquisition integration. The first quarter gives a good first answer, but not a complete one.

Demand Is Proven, Margin Expansion Is Not

The strong number in the quarter is not only the 38.6% increase in sales. It is the fact that all three segments posted positive organic growth. Taste grew 34.4%, including 8.8% currency-neutral organic growth. Fragrance jumped 79.5%, but even there organic growth was 10.0%. Specialty fine ingredients grew 13.8%, with 9.0% organic growth, and unlike late 2025 the segment already posted a 13.0% operating margin, almost unchanged from the parallel quarter.

The issue is that the improvement does not flow evenly to operating profit. Gross profit rose to $35.0 million and gross margin improved to 41.9%, but R&D, selling and marketing, and G&A all grew alongside the group. Operating profit was $12.9 million, or 15.4% of sales, versus 16.0% in the parallel quarter. Even after excluding $0.5 million of other expenses, operating margin was still 16.0%. The quarter proved demand and scale, but it did not yet prove broad operating leverage.

Net profit looks especially strong: $11.1 million, up 104.5%. That needs a quality-of-earnings split. Net finance expense turned into $1.05 million of finance income, mainly due to non-cash finance income from the early payment of the put option to acquire the remaining Attractive Scent shares. On a Non-GAAP basis, net profit was $11.7 million, up 48.8%, which is probably closer to the recurring earnings signal than the doubling of reported net profit.

The May Deals Change The Next Balance Sheet

The first quarter closed before two important acquisitions, so it is mostly a starting point rather than a full 2026 picture. On May 1, 2026, the company completed the acquisition of 100% of Phoenix in the United States for $95 million, plus up to $5 million of contingent consideration based on second- and third-quarter 2026 performance. The consideration includes repayment of roughly $63 million of net debt and working-capital and net-debt adjustments to be finalized within two quarters. The deal was funded from the company's own resources, so it will show up in the balance sheet only after the March 31 cut-off.

Phoenix adds a broader U.S. operating base: 2025 sales of $36.8 million, adjusted EBITDA of $6.9 million, and an 18.8% adjusted EBITDA margin. The presentation splits that into a business where most sales, $30.3 million, come from fragrances, with another $6.5 million from flavors. This is a relatively large asset for the group's recent acquisition pace, so the test raised in the earlier Phoenix analysis now matters more: not only the purchase price, but how quickly Klabin-Turpaz moves production into Phoenix's New Jersey facility, and whether the stated $2 million of expected synergies arrive without hurting customer relationships and margins.

On May 12, 2026, the company also completed the acquisition of 70% of Romessence in France for EUR 22.6 million, funded with long-term bank financing. This is a different story. Romessence is based in Grasse, sells mainly into fine fragrances, and generated 2025 sales of EUR 8.9 million and adjusted EBITDA of EUR 2.5 million, a 28.1% margin. Together with Attractive Scent, it strengthens the fragrance division at a higher-quality point in the market. The less comfortable side is the put/call mechanism over the remaining 30% of the shares, exercisable three years after closing, at a price based on Romessence's performance and payable in cash or Turpaz shares at the founders' choice. That adds another layer to an already crowded acquisition-liability picture.

Cash Decides How Comfortable The Growth Stays

On the surface balance sheet, the company entered the May acquisitions with comfortable room. At the end of March it had $139.8 million of cash and cash equivalents, net debt of $35.5 million, and a net debt to EBITDA ratio of 0.5 versus a bank covenant ceiling of 3.5. Equity was $299.3 million, or 41.9% of the balance sheet, far above the minimum bank requirements.

The cash reading is less clean. Cash flow from operations was $5.8 million versus net profit of $11.1 million, mainly because receivables increased by $13.4 million and inventory increased by $2.2 million. That is not a broken signal, because operating working capital as a percentage of sales stayed broadly similar, 27.6% versus 26.6% at the end of 2025. It is still a reminder that growth consumes cash before it releases it.

The all-in cash picture for the quarter includes positive operating cash flow, roughly $2.5 million of investments, $5.0 million of purchase-liability repayments, $5.8 million of long-term loan repayments, and $1.2 million of lease repayments. In addition, the board approved a $6.8 million dividend that was paid on April 29, 2026. This is not an immediate liquidity problem, but after Phoenix and Romessence it makes 2026 a year in which cash, debt, and acquisition liabilities will work harder.

The financial instruments note explains why this is the central checkpoint. Put-option and contingent-consideration liabilities totaled $113.7 million at the end of March, and their value is based on the expected EBITDA of acquired companies, using a 7.4% weighted discount rate. In other words, part of the risk does not appear as ordinary bank debt. It sits in a liability that moves with acquired-company performance. If Phoenix and Romessence keep their margins and create synergies, that layer is manageable. If margins erode or working capital keeps growing quickly, the market will start focusing less on sales run-rate and more on the cost of digestion.

Conclusions

The first quarter leaves a positive but unfinished read. Demand is there, organic growth is broader, and specialty fine ingredients no longer look like the weak link of late 2025. On the other hand, the large May acquisitions are not yet reflected in the quarter's numbers, and operating cash flow is still materially lower than net profit because of working capital. 2026 is a proof year: preserving fragrance margins, sustaining the improvement in specialty fine ingredients, and absorbing Phoenix without a jump in working capital or debt. If that happens, the company will show that its acquisition machine is building a platform, not only revenue. If it does not, the market will get a company that grows quickly but demands more cash, more debt, and more trust in every additional deal.